Kapspargo Sprinkle is a drug owned by Sun Pharma Industries Ltd. It is protected by 2 US drug patents filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 09, 2035. Details of Kapspargo Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9504655 | Capsule dosage form of metoprolol succinate |
Jul, 2035
(10 years from now) | Active |
| US9700530 | Capsule dosage form of metoprolol succinate |
Jul, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Kapspargo Sprinkle's patents.
Latest Legal Activities on Kapspargo Sprinkle's Patents
Given below is the list of recent legal activities going on the following patents of Kapspargo Sprinkle.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 May, 2024 | US9504655 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2021 | US9700530 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2020 | US9504655 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Jul, 2017 | US9700530 |
| Recordation of Patent Grant Mailed Critical | 11 Jul, 2017 | US9700530 |
| Email Notification Critical | 22 Jun, 2017 | US9700530 |
| Issue Notification Mailed Critical | 21 Jun, 2017 | US9700530 |
| Application Is Considered Ready for Issue Critical | 14 Jun, 2017 | US9700530 |
| Dispatch to FDC | 14 Jun, 2017 | US9700530 |
| Issue Fee Payment Received Critical | 12 Jun, 2017 | US9700530 |
US patents provide insights into the exclusivity only within the United States, but Kapspargo Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Kapspargo Sprinkle's family patents as well as insights into ongoing legal events on those patents.
Kapspargo Sprinkle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kapspargo Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 09, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kapspargo Sprinkle Generic API suppliers:
Metoprolol Succinate is the generic name for the brand Kapspargo Sprinkle. 23 different companies have already filed for the generic of Kapspargo Sprinkle, with Granules having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Kapspargo Sprinkle's generic
About Kapspargo Sprinkle
Kapspargo Sprinkle is a drug owned by Sun Pharma Industries Ltd. Kapspargo Sprinkle uses Metoprolol Succinate as an active ingredient. Kapspargo Sprinkle was launched by Spil in 2018.
Approval Date:
Kapspargo Sprinkle was approved by FDA for market use on 26 January, 2018.
Active Ingredient:
Kapspargo Sprinkle uses Metoprolol Succinate as the active ingredient. Check out other Drugs and Companies using Metoprolol Succinate ingredient
Dosage:
Kapspargo Sprinkle is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG TARTRATE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| EQ 200MG TARTRATE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| EQ 50MG TARTRATE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| EQ 25MG TARTRATE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |